Opinion

Video

Understanding CML: Your Journey from Diagnosis to Treatment

Author(s):

Jorge E. Cortes, MD,Joannie Clements

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • Please provide some background on CML. What are the different subtypes of CML and how do they differ in terms of presentation and management?
  • Can you explain the typical prognosis and disease course for someone diagnosed with CML? How do you educate newly diagnosed patients on what to expect?

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of doctor with text.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Illustration of doctor.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Dr. Richard “Rick" Winneker
Related Content
Image of blood cells.
July 25th 2025

FDA Approves Doptelet With Sprinkle Form for Pediatric Immune Thrombocytopenia

Spencer Feldman
Doptelet and new oral sprinkle granules is approved for children one year and older with chronic immune thrombocytopenia, showing 28% durable platelet response in study.
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
January 15th 2024

FDA Gives Cancer Drug Updates, Prostate Cancer Trial Enrolls Patients

Alex Biese Brielle Benyon
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
Experts discuss treatment options for those with ER-positive, HER2-negative stage 4 breast cancer: © stock.adobe.com.
July 9th 2025

Understanding Therapeutic Options for ER+/HER2- Metastatic Breast Cancer

Kristie L. Kahl
Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, HER2-negative stage 4 breast cancer.
Treating Waldenstrom’s Macroglobulinemia
December 17th 2020

Treating Waldenstrom’s Macroglobulinemia

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
Chronic conditions from Waldenström macroglobulinemia can affect quality of life over time.
July 1st 2025

Survival, Symptoms and Support in Waldenström Macroglobulinemia

Spencer Feldman
Waldenström macroglobulinemia is often slow growing, with a 78% five-year survival rate, but chronic conditions can affect quality of life over time.
At age 19, stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope: © stock.adobe.com.
June 28th 2025

This Wasn't the Plan: When the World Shifted After Cancer

Anushree Thakur
At age 19, I was a medical student with big dreams — until stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope.